However, whilst concerns have been raised over the safety of incretin-based treatments for those living with both cancer and diabetes meta-analysis of clinical data has not revealed any association between the development of lung [122], gastrointestinal [123] or pancreatic [124] cancer and the prescriptions of the incretin analogues. This evidence concerns the gene GCG and cancer.